🔬🩸 Hematology Updates: DARZALEX, CAR NK Breakthroughs, and Triplet AML Therapy Momentum
From CHMP approvals and pediatric trial expansions to novel cell therapies and pivotal trial data—this week’s hematology roundup highlights the key milestones transforming blood cancer treatment and rare hematologic care.
đź’ˇ Key Highlights This Week:
âś… DARZALEX earns CHMP backing for early use in high-risk smouldering multiple myeloma, reducing progression risk by 51 percent
👶 Moleculin gains FDA approval to enroll infants in its Annamycin + cytarabine pediatric AML trial
🧬 Senti Bio receives Orphan Drug Designation for SENTI-202, a logic-gated CAR NK therapy targeting CD33 or FLT3
🧫 CERo Therapeutics’ phagocytic T cell therapy CER-1236 secures orphan status for AML
đź’° Aptose and Hanmi secure $8.5M in funding to advance their tuspetinib + venetoclax + azacitidine AML triplet regimen
⚠️ AbbVie’s VERONA trial in high-risk MDS fails to meet its primary endpoint for overall survival improvement
🔬 Genmab reports 87% response and 100% survival at 6 months with epcoritamab + R-ICE in relapsed/refractory DLBCL
💊 Roche’s Lunsumio + Polivy combo triples PFS and doubles CR in relapsed large B-cell lymphoma
🧠Bristol Myers’ Breyanzi hits greater than 95 percent response with 62.1% CR and durable remission in marginal zone lymphoma
🧵 Zemcelpro receives positive CHMP opinion for patients lacking suitable stem cell donors, with EU decision expected in 2 months
🩸 Grifols’ BT524 meets Phase 3 endpoint for acquired fibrinogen deficiency, lowering blood loss and thromboembolic risk
🎯 Whether you’re tracking next-gen immunotherapies, pediatric trial expansion, or regulatory movement in AML and lymphoma—this week’s update brings the most impactful insights in hematology.
📢 Stay Ahead in Hematology Research!
âś… Like, share, and subscribe for weekly updates on blood cancers, cell therapies, and global clinical breakthroughs.
#Hematology #MultipleMyeloma #AML #MDS #DLBCL #CAR_T #OrphanDrug #PediatricTrials #ClinicalTrials #BloodCancer #LucidQuest #BiotechNews #CellTherapy #PharmaInnovation #Breyanzi #Polivy #Tuspetinib #HealthcareUpdates #Fibrinogen #Venetoclax